Want to see LCTX full AI Analyst Report?
LCTX Stock Chart & Stats
$1.03
$0.00(0.00%)
At close: 4:00 PM EDT
$1.03
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.00 - $2.09
Previous Close$1.04
Volume1.71M
Average Volume (3M)1.74M
Market Cap
$268.08M
Enterprise Value$292.88
Total Cash (Recent Filing)$50.83M
Total Debt (Recent Filing)$2.30M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 05, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding252,907,470
10 Day Avg. Volume986,098
30 Day Avg. Volume1,742,930
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.63
Price to Sales (P/S)26.40
P/FCF Ratio-19.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside579.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$12.51M
Bulls Say, Bears Say
Bulls Say
Scalable GMP Manufacturing (AlloSCOPE)AlloSCOPE provides a durable operational advantage: a validated 2-tier GMP bank and reuse across cell types reduces time and cost to advance programs. FDA-cleared bank material and reuse capability increase technical defensibility, accelerate pipeline expansion, and lower per-dose manufacturing risk long-term.
Strategic Partnerships And Commercial OptionalityDeep collaborations with Roche/Genentech and funded preclinical work with Demant provide validation, potential non-dilutive funding, and access to regulatory and commercial expertise. Partner-led trial expansion and milestone upside materially de-risk development and sustain program funding prospects over multiple years.
Conservative Balance Sheet And Extended RunwayA low-debt balance sheet plus ~$50.8M in cash and stated runway into Q3 2028 gives management time to execute clinical milestones without immediate refinancing pressure. Combined with lower opex versus prior year, this structural liquidity supports steady R&D progress and partnership-driven value realization over the medium term.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow indicates the company burns cash to fund R&D and operations. Over time this requires repeated financing, which risks dilution or restrictive financing terms, constrains discretionary program investment and may slow development if capital markets tighten or partner payments lag.
Reliance On Contingent Funding SourcesMaterial dependence on warrant exercises and partner milestones creates structural funding risk: these sources are timing- and outcome-dependent. Delays or non-realization would force equity raises or program cuts, increasing execution uncertainty and potentially lengthening timelines for key clinical programs.
Major Scale-up Challenge For Islet Program (ILT1)The ~5,000x higher cell-dose requirement for ILT1 versus OpRegen is a structural technical and cost hurdle. Scaling suspension manufacturing to that magnitude raises yield, cost, supply chain and regulatory hurdles that may require new tech or partners; failure to solve it would limit commercial viability of ILT1.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $1.00 and its highest was $2.09 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $268.08M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.002.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 252,907,470 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went down -2.655%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (579.61% Upside)
$7.00 (579.61% Upside)
Blogger Sentiment
Bullish
LCTX Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 6.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.98%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful technical and strategic progress: demonstrated scalable GMP manufacturing (AlloSCOPE), rapid internal pipeline expansion (COR1, ILT1, ReSonance), and partnership validation (Roche/Genentech, Demant). Financial reporting showed an apparent improvement to net income, extension of cash runway into Q3 2028, and an incremental $4.6M ATM raise. However, material weaknesses and near-term risks remain: Q2 revenue dropped substantially (~60.7% YoY), reported profitability was driven by noncash accounting items, cash runway still depends on contingent exercises/milestones, OpRegen advancement timing is dependent on partner-driven surgical optimization, and ILT1 faces major manufacturing scale challenges. Overall, positives around technology, partnerships and program breadth are tempered by funding, revenue dynamics and technical/partner-dependent execution risks.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$7.00
▲(579.61% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
13.78% Insiders
4.55% Mutual Funds
23.05% Other Institutional Investors
51.12% Public Companies and
Individual Investors